This repository contains a comprehensive critical commentary of the research article “Anti-progestin therapy targets hallmarks of breast cancer risk” by Simoes et al., published in Nature (2025). The original study proposes that anti-progestin agents can suppress proliferative, stem-like, and microenvironmental features in human breast tissues and mouse models, thereby potentially reducing breast cancer risk. While the topic is of significant biomedical and clinical interest, rigorous scrutiny reveals substantial methodological, analytical, and interpretational weaknesses that limit the strength of the study’s conclusions. This commentary offers a detailed, figure-by-figure evaluation of the main figures, Extended Data Figures, and Supplementary Figures, highlighting these concerns in a systematic and evidence-driven manner. Key issues addressed in this commentary include insufficient donor metadata in human breast explant experiments, inadequate control and normalization of imaging data, unclear statistical frameworks, inconsistent gating strategies in flow cytometry, potential batch effects in transcriptomic analyses, and over-interpretation of surrogate markers as indicators of breast cancer risk. Several figures reveal imaging artifacts, field-of-view inconsistencies, or potential pseudoreplication. The commentary also emphasizes the lack of essential negative controls, incomplete reporting of experimental conditions, and missing validation using independent datasets. Collectively, these omissions raise concerns regarding the reproducibility and robustness of the study’s core claims. The repository includes extensive critiques of: Main Figures 1–5, covering proliferation assays, organoid and explant responses, mouse model outcomes, transcriptional signature analyses, and immune/microenvironmental remodeling assessments. Extended Data Figures 1–20, addressing donor variability, flow cytometry gating, whole-mount mammary gland imaging, bulk and single-cell RNA-seq quality, tissue morphology quantification, cytokine profiling, menstrual-cycle influences, and potential inconsistencies in stromal imaging. Supplementary Figures 1–10, including Western blots of PR isoforms, ligand-binding assays, cell-cycle analyses, organoid viability assays, inflammatory gene signatures, and limited pilot tumorigenesis data. Across these evaluations, the commentary identifies pervasive gaps in transparency, insufficient image standardization, inconsistent assay interpretation, and weak connections between molecular markers and validated predictors of cancer incidence. Although the study touches on compelling biological questions regarding progesterone signaling and breast tissue dynamics, the evidence presented does not substantiate broad conclusions about anti-progestin therapy as a reliable means of reducing breast cancer risk. This Zenodo article is intended as a resource for researchers, clinicians, peer reviewers, and methodologists interested in improving the rigor, reproducibility, and interpretability of translational breast cancer research. By dissecting the experimental logic, data presentation practices, and analytical strategies used in the original publication, this work encourages constructive scientific dialogue and more cautious interpretation of surrogate biomarkers in risk-reduction studies. The commentary also underscores the importance of transparent reporting, donor-level metadata, raw data availability, and rigorous validation across experimental systems when addressing complex endocrine mechanisms in breast cancer biology. All content is provided for scholarly discussion and scientific integrity purposes.